- Home
- LOAN vs BTAI Comparison
LOAN vs BTAI Comparison
Compare LOAN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | BTAI |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 36.5M |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LOAN | BTAI |
|---|---|---|
| Price | $4.38 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 19.2K | ★ 301.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.04% | N/A |
| EPS Growth | ★ 2.08 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $9,688,641.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $261.81 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.29 | $1.17 |
| 52 Week High | $6.05 | $8.08 |
Technical Indicators
Market Signals| Indicator | LOAN | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 49.74 |
| Support Level | $4.29 | $1.50 |
| Resistance Level | $4.59 | $1.72 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 8.97 | 49.06 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.